Selank Molecular Structure & Chemical Properties

Selank represents a pioneering development in synthetic anxiolytic peptides, with over two decades of research conducted primarily at the Institute of Molecular Genetics of the Russian Academy of Sciences. Originally developed in the 1990s as a synthetic analog of tuftsin – a naturally occurring immunomodulatory peptide fragment derived from immunoglobulin G – Selank was specifically engineered to provide anxiolytic and nootropic effects with enhanced metabolic stability. The peptide’s structure features the core tuftsin sequence extended by a proline-glycine-proline tripeptide at the C-terminus, a modification that significantly prolongs its duration of action compared to the endogenous parent molecule while maintaining favorable safety characteristics that have distinguished it from classical benzodiazepine anxiolytics.

Chemical Structure

2D molecular structure (Source: PubChem)

Technical Specifications

The peptide’s extended structure incorporates four proline residues that provide conformational rigidity and resistance to enzymatic degradation, contributing to improved pharmacological properties compared to the native tuftsin tetrapeptide sequence.

Selank Mechanism of Action

Selank peptide exerts its anxiolytic and nootropic effects through multiple interconnected neurochemical pathways rather than a single receptor target. Research indicates that allosteric modulation of GABAergic neurotransmission serves as the primary mechanism underlying its anxiolytic effects, complemented by actions on monoamine systems, enkephalin metabolism, and neurotrophic factor expression that collectively contribute to its diverse biological activities.

Primary Cellular Pathways

GABAergic System Modulation – Anxiolytic Effects

Studies have demonstrated that Selank influences GABA-A receptor function through allosteric modulation rather than direct receptor binding. Research examining gene expression patterns in rat frontal cortex revealed that Selank administration (300 mcg/kg) altered the expression of 45 genes involved in GABAergic neurotransmission within one hour, producing effects similar to those observed with GABA itself. Key findings include:

• Modulation of GABA-A receptor subunit expression and affinity
• Changes in specific binding site density for radiolabeled GABA
• Effects comparable to benzodiazepines but without associated side effects
• Influence on GABA transporter expression, particularly GAT-2

This mechanism accounts for Selank’s anxiolytic properties that mirror classical benzodiazepines while avoiding the sedation, dependence, and withdrawal syndromes characteristic of that drug class.

Enkephalin-Degrading Enzyme Inhibition

Research indicates Selank peptide significantly inhibits enzymes responsible for enkephalin degradation in plasma, potentially extending the half-life of endogenous enkephalins. Investigations demonstrated:

• Dose-dependent inhibition of enkephalin-degrading enzymes (IC50 approximately 15 micromolar)
• Greater potency than reference peptidase inhibitors bacitracin and puromycin
• Increased leu-enkephalin half-life in BALB/c mice following 100 mcg/kg administration
• Correlation between enkephalinase inhibition and anxiolytic activity

The stabilization of enkephalins, natural opioid peptides involved in pain modulation and stress response, represents a unique mechanism contributing to Selank’s effects.

Monoamine Neurotransmitter Modulation

Studies examining neurotransmitter content in mouse brain regions revealed strain-specific effects on dopamine, serotonin, and norepinephrine systems. Research showed:

• Serotonin metabolism enhancement within 30 minutes of administration
• Differential effects on dopamine metabolites (DOPAC and HVA) between mouse strains
• Restoration of serotonin levels despite serotonin synthesis inhibition
• Modulation of dopamine receptor gene expression (DRD1A and DRD2)

These actions on monoaminergic systems contribute to Selank’s nootropic and mood-regulating properties.

Brain-Derived Neurotrophic Factor (BDNF) Upregulation

Research demonstrated that Selank peptide rapidly increases BDNF expression in the hippocampus of rats, a key mechanism underlying potential cognitive and neuroprotective effects. Investigations revealed:

• Rapid elevation of BDNF mRNA in hippocampal regions
• Protection against ethanol-induced cognitive impairment through BDNF regulation
• BDNF increases in both hippocampus and prefrontal cortex
• Potential mechanisms for memory consolidation enhancement

BDNF upregulation supports neuroplasticity and may explain Selank’s nootropic properties observed in learning and memory studies.

Immunomodulatory Actions

As a tuftsin analog, Selank exhibits immunomodulatory properties distinct from its central nervous system effects. Research documented:

• Modulation of interleukin-6 (IL-6) expression in patients with anxiety disorders
• Effects on T-helper cell cytokine balance (Th1/Th2 ratios)
• Antiviral activity against influenza, herpes simplex, and cytomegalovirus
• Influence on inflammation-related gene expression in spleen tissue

Selank Research Applications & Key Findings

Anxiety and Stress-Related Research

Anxiolytic Effects in Preclinical Models

Extensive research in rodent anxiety models has examined Selank’s stress-reducing properties. Studies using elevated plus-maze and open-field tests demonstrated significant anxiolytic activity in multiple species. Key findings include:

• Reduced anxiety behaviors in BALB/c mice at 100-300 mcg/kg doses
• Strain-specific effects with pronounced activity in high-anxiety mouse strains
• Anxiolytic potency comparable to diazepam without sedative effects
• Enhanced efficacy in combination with low-dose benzodiazepines

Research in chronic unpredictable mild stress models showed that Selank (50 mcg/kg daily) prevented stress-induced behavioral deterioration and maintained baseline anxiety indicators comparable to pre-stress levels.

Clinical Investigations in Anxiety Disorders

Human clinical studies conducted in Russia examined Selank’s therapeutic potential. A comparative trial in 62 patients with generalized anxiety disorder (GAD) and neurasthenia evaluated Selank (30 patients) versus medazepam (32 patients) over 14 days. Results demonstrated:

• Comparable anxiolytic efficacy to benzodiazepine treatment
• Additional antiasthenic (anti-fatigue) and psychostimulant effects not observed with benzodiazepines
• Correlation between leu-enkephalin half-life normalization and clinical improvement
• Absence of withdrawal symptoms, dependence, or cognitive impairment

Additional studies comparing Selank to phenazepam confirmed similar anxiolytic activity with superior tolerability profiles.

Cognitive Function and Learning Research

Memory and Learning Enhancement

Research in rat models assessed Selank’s nootropic properties using various learning paradigms. Studies employing active avoidance conditioning demonstrated:

• Significant learning process activation in rats with initially poor learning ability
• Effects apparent after first dose on training day one (300 mcg/kg)
• Progressive improvement with repeated administration over four days
• Increased correct responses and decreased errors in memory tasks

Investigations comparing Selank to piracetam showed comparable or superior memory enhancement at substantially lower doses.

Protection Against Cognitive Impairment

Studies examining cognitive protection under various challenge conditions revealed:

• Attenuation of alcohol-induced memory deficits in chronic ethanol exposure models
• Protection against hypoxia-induced cognitive impairment
• Restoration of learning ability in neurotoxin-damaged models
• Prevention of BDNF reduction associated with cognitive dysfunction

Research in rats with 30-week alcohol exposure showed Selank-treated animals maintained object recognition performance and avoided attention deficits observed in untreated subjects.

Neurochemical and Gene Expression Research

Neurotransmitter System Effects

Comprehensive investigations examined Selank’s influence on brain neurochemistry across multiple regions. Studies analyzing monoamine content in hippocampus, frontal cortex, and hypothalamus documented:

• Differential dopamine and serotonin modulation between brain regions
• Strain-specific responses in neurotransmitter systems
• Enhanced serotonin metabolism in rats pre-treated with synthesis inhibitors
• Time-dependent changes in neurotransmitter metabolite ratios

Research demonstrated these neurochemical changes correlated with behavioral and cognitive effects observed in functional studies.

Gene Expression Profiling

Molecular investigations using quantitative PCR methods revealed Selank’s influence on gene expression patterns. Studies examining 84 genes involved in neurotransmission showed:

• Changes in 45 gene expression levels one hour post-administration
• Sustained alterations in 22 genes at three hours
• High correlation between Selank peptide and GABA-induced expression changes
• Unique gene targets including dopamine receptors and GABA transporters

These molecular findings provide mechanistic insights into Selank’s rapid onset and sustained effects.

Additional Research Applications

Research has explored Selank’s potential in various other experimental contexts:

• Morphine withdrawal attenuation – reducing aversive withdrawal signs in opioid-dependent rats
• Alcohol withdrawal management – decreasing anxiety during alcohol cessation in motivated rat models
• Antidepressant-like effects – reducing immobility in forced swim test, a standard depression model
• Metabolic syndrome parameters – influencing lipid profiles and glucose regulation in preliminary studies

Selank Peptide Pharmacokinetics & Metabolism

Absorption & Distribution

Selank exhibits pharmacokinetic properties typical of small peptides, with research demonstrating activity via multiple administration routes. Following administration in rodent models:

• Rapid systemic distribution following intranasal or intraperitoneal administration
• Peak biological effects observed within 15-30 minutes of intranasal delivery
• Penetration across the blood-brain barrier to reach central nervous system targets
• Preferential uptake in well-vascularized organs including liver, kidney, and heart

Intranasal administration studies revealed that despite rapid plasma clearance, central nervous system effects persisted for hours, suggesting either tissue retention or sustained signaling cascade activation independent of plasma concentrations.

Metabolism & Elimination

The metabolic fate of Selank peptide is characterized by rapid degradation typical of unmodified peptides, despite structural modifications intended to enhance stability. Pharmacokinetic investigations indicate:

• Plasma half-life of 2-10 minutes in rat and mouse models
• Complete clearance from detectable plasma levels within 10 minutes
• Likely degradation through peptidase activity and proteolytic cleavage
• No unchanged peptide or identifiable metabolites detected in urine

A critical pharmacokinetic paradox exists: despite plasma clearance within minutes, behavioral and neurochemical effects persist for 12-24 hours or longer. This disconnect suggests either formation of active metabolites, tissue sequestration with slow release, or initiation of long-lasting intracellular signaling cascades that outlive parent compound presence.

Excretion Pathways

Limited characterization of excretion routes indicates:

• Renal elimination likely for peptide fragments following proteolytic degradation
• No detection of intact peptide in urine following single-dose administration
• No evidence of bioaccumulation in chronic dosing studies (rat models)
• Hepatic metabolism may contribute to peptide fragment processing

The rapid elimination kinetics combined with prolonged pharmacodynamic effects represent a unique aspect requiring further investigation to fully characterize Selank’s pharmacological profile.

Selank Research Protocols & Administration

Dosing in Published Research

Research investigations have employed various Selank peptide doses depending on species, experimental model, and intended outcome:

• Rat studies: 300 mcg/kg most common anxiolytic dose (range: 50-500 mcg/kg)
• Mouse models: 100-300 mcg/kg typical range for behavioral studies
• Human clinical trials: 0.15-0.6 mg administered intranasally 2-3 times daily
• Cell culture studies: 1-100 micromolar concentrations for mechanistic investigations

Important: These are experimental doses used in specific research contexts and cannot be extrapolated to other species due to profound differences in metabolism, peptide degradation rates, receptor distribution patterns, and pharmacokinetic profiles. Species-specific factors fundamentally influence both efficacy and safety profiles of peptide therapeutics.

Administration Routes in Research

Multiple delivery methods have been investigated in preclinical and clinical studies:

• Intranasal administration – Preferred route in human studies; allows blood-brain barrier penetration
• Intraperitoneal injection – Standard route in rodent behavioral research; reliable systemic delivery
• Subcutaneous injection – Used in some animal protocols; slower absorption kinetics
• Local application – Investigated in immunomodulation studies
• Intravenous injection – Employed primarily in pharmacokinetic characterization studies

Intranasal delivery demonstrates particular advantages for central nervous system-targeted effects while avoiding first-pass hepatic metabolism.

Common Model Organisms

Selank has been studied across multiple experimental systems:

• Rats – Primary model for behavioral, neurochemical, and gene expression studies (Wistar, Sprague-Dawley strains)
• Mice – Used extensively for strain-comparison studies (BALB/c, C57Bl/6 strains); genetic models
• Human subjects – Limited clinical trials in Russian and CIS populations with anxiety disorders
• Cell culture – Neuroblastoma cell lines (IMR-32), primary neurons, immune cells

The majority of mechanistic and safety data derives from rodent models, with human data limited to short-term clinical observations in specific populations.

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite decades of research activity, Selank faces substantial translational barriers that limit its widespread adoption in international research and preclude broader clinical application.

Geographic Concentration of Research

The overwhelming majority of Selank research originates from Russian institutions, presenting significant limitations:

• Nearly all studies conducted by Russian Academy of Sciences or affiliated institutions
• Limited independent replication by international research groups
• Language barriers limiting accessibility of Russian-language publications
• Potential publication bias favoring positive findings

This geographic concentration of research creates uncertainty regarding reproducibility and generalizability of reported findings.

Human Clinical Data Limitations

Human clinical evidence remains severely constrained:

• Only 3-4 published human studies available in English-language databases
• All human trials conducted in Russian or CIS populations
• No large-scale Phase III clinical trials in diverse populations
• Short-term treatment protocols only (2-4 weeks maximum)
• No long-term safety data beyond brief treatment periods
• Absence of pediatric, geriatric, or special population studies

Mechanistic Understanding Gaps

Fundamental aspects of Selank’s mechanism remain incompletely characterized:

• Primary molecular target or receptor not definitively identified
• Relationship between rapid plasma clearance and prolonged effects unexplained
• Contribution of parent peptide versus potential metabolites unclear
• Strain-specific and individual variability mechanisms not fully elucidated
• Gene expression changes require validation in additional model systems

Long-Term Safety Considerations

Critical safety questions remain unanswered:

• Chronic use effects beyond several weeks unstudied even in animals
• Potential for tachyphylaxis or tolerance with extended use unknown
• Effects on developing nervous systems not characterized
• Pregnancy and lactation safety completely unstudied
• Drug-drug interaction potential uncharacterized
• Long-term immunological effects of repeated dosing unclear

Regulatory & Availability Status

FDA Position

Selank peptide has not received FDA approval for any indication in the United States:

• Not approved for human therapeutic use
• Not recognized as Generally Recognized as Safe (GRAS)
• Not legally available for medical compounding in the United States
• Classified as a research chemical for laboratory use only
• No established therapeutic use basis

The FDA has not issued specific warning letters regarding Selank, but the peptide falls under general policies regarding unapproved drug substances that cannot be marketed for human use.

International Regulatory Status

Regulatory classification varies significantly by jurisdiction:

• Approved as pharmaceutical in Russia and select Commonwealth of Independent States (CIS) countries for generalized anxiety disorder
• Not authorized as medicine in European Union member states
• Unavailable through regulatory channels in United Kingdom, Canada, and Australia
• Often marketed as “research chemical” in jurisdictions without explicit prohibition

WADA Status

Current World Anti-Doping Agency classification:

• Selank does not appear on the current WADA Prohibited List as of 2025
• However, could potentially fall under Section S0 (Non-Approved Substances) depending on interpretation
• Lack of widespread regulatory approval may create ambiguity for competitive athletes
• Athletes should verify current status with national anti-doping organizations before use

Research Classification: Selank is available for laboratory research use only in most jurisdictions. It is not intended for human consumption, medical use, or veterinary applications outside countries where explicitly approved. All research must be conducted under appropriate ethical oversight and regulatory compliance with institutional review board approval where applicable.

References

1. Volkova, A., Shadrina, M., Kolomin, T., Andreeva, L., Limborska, S., Myasoedov, N., & Slominsky, P. (2016). Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Frontiers in Pharmacology, 7, 31. PubMed
   
2. Kasian, A., Kolomin, T., Andreeva, L., Bondarenko, E., Myasoedov, N., Slominsky, P., & Shadrina, M. (2017). Peptide Selank enhances the effect of diazepam in reducing anxiety in unpredictable chronic mild stress conditions in rats. Behavioural Neurology, 2017, 5091027. PubMed
   
3. Medvedev, V.E., Tereshchenko, O.N., Kost, N.V., Ter-Israelyan, A.Y., Gushanskaya, E.V., Chobanu, I.K., Sokolov, O.Y., & Myasoedov, N.F. (2008). Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 108(4), 38-48. PubMed
   
4. Kozlovskii, I.I., & Danchev, N.D. (2003). The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats. Neuroscience and Behavioral Physiology, 33(7), 639-643.
5. Kolik, L.G., Nadorova, A.V., & Seredenin, S.B. (2019). Selank, peptide analogue of tuftsin, protects against ethanol-induced memory impairment by regulating of BDNF content in the hippocampus and prefrontal cortex in rats. Bulletin of Experimental Biology and Medicine, 167(5), 641-644. PubMed
   
6. Zozulya, A.A., Kost, N.V., Sokolov, O.Y., Gabaeva, M.V., Grivennikov, I.A., Andreeva, L.N., Zolotarev, Y.A., Ivanov, S.V., Andryushchenko, A.V., Myasoedov, N.F., & Smulevich, A.B. (2001). The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine, 131(4), 315-317. PubMed
   
7. Seredenin, S.B., Kost, N.V., & Voronina, T.A. (2002). Effects of heptapeptide Selank on behavioral reactions and activities of plasma enkephalin-degrading enzymes in mice with different phenotypes of emotional and stress reactions. Bulletin of Experimental Biology and Medicine, 134(5), 428-431. PubMed
   
8. Narkevich, V.B., Kudrin, V.S., Klodt, P.M., Pokrovskii, A.A., Kozlovskaia, M.M., Maiskii, A.I., & Raevskii, K.S. (2008). Effects of heptapeptide selank on the content of monoamines and their metabolites in the brain of BALB/C and C57Bl/6 mice: a comparative study. Eksperimentalnaia i Klinicheskaia Farmakologiia, 71(5), 8-12. PubMed
   
9. Semenova, T.P., Kozlovskii, I.I., Zakharova, N.M., & Kozlovskaia, M.M. (2010). Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA. Eksperimentalnaia i Klinicheskaia Farmakologiia, 72(4), 6-8. PubMed
   
10. Filatova, E., Kasian, A., Kolomin, T., Rybalkina, E., Alieva, A., Andreeva, L., Limborska, S., Myasoedov, N., Pavlova, G., Slominsky, P., & Shadrina, M. (2017). GABA, Selank, and Olanzapine affect the expression of genes involved in GABAergic neurotransmission in IMR-32 cells. Frontiers in Pharmacology, 8, 89. PubMed
    
11. Andreeva, L.A., Nagaev, I.Y., Mezentseva, M.V., Shapoval, I.M., Podchernyaeva, R.Y., Shcherbenko, V.E., Potapova, L.A., Russu, L.I., Ershov, F.I., & Myasoedov, N.F. (2010). Antiviral properties of structural fragments of the peptide Selank. Doklady Biological Sciences, 431, 79-82. PubMed
    
12. Kolomin, T.A., Agapova, T.Y., Agniullin, Y.V., Shram, S.I., Shadrina, M.I., Slominskii, P.A., Limborskaia, S.A., & Myasoedov, N.F. (2013). The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. Peptides, 47, 66-71. PubMed
    
13. Konstantinopolsky, M.A., Chernyakova, I.V., & Kolik, L.G. (2017). Selank, a peptide analog of tuftsin, attenuates aversive signs of morphine withdrawal in rats. Bulletin of Experimental Biology and Medicine, 162(3), 333-336. PubMed
    
14. Kolik, L.G., Nadorova, A.V., & Kozlovskaya, M.M. (2014). Efficacy of peptide anxiolytic selank during modeling of withdrawal syndrome in rats with stable alcoholic motivation. Bulletin of Experimental Biology and Medicine, 157(1), 52-55. PubMed
    
15. Medvedev, V.E., Tereshchenko, O.N., Israelian, A.I., Chobanu, I.K., Kost, N.V., Sokolov, O.I., & Myasoedov, N.F. (2014). A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 114(7), 17-22. PubMed
    

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. Selank is intended for laboratory research use only.